El interés en corto de Pacer Trendpilot 100 ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Pacer Trendpilot 100 ETF. Los datos de interés en corto se actualizan cada dos semanas.

Pacer Trendpilot 100 ETF (NASDAQ:PTNQ), Informe de interés en corto

Pacer Trendpilot 100 ETF

Technology

Consumer Cyclical

Other

Communication Services

Consumer Defensive

Industrials

Healthcare

Utilities

Basic Materials

Energy

Financial Services

Real Estate

The Fund employs a passive management (or indexing) investment approach designed to track the total return performance, before fees and expenses, of the Index. The Index is based on a proprietary methodology developed and maintained by Index Design Group (the Index Provider), an affiliate of Pacer Advisors, Inc., the Funds investment adviser (the Adviser).

Microsoft Corp

Apple Inc

Nvidia Corp.

Amazon.Com Inc

Broadcom Inc

Meta Platforms, Inc.

Alphabet Inc

Tesla, Inc.

Costco Wholesale Corp.

Netflix, Inc.

Biotech

News

General

SRPT

Reuters Reports FDA Investigating Deaths Due To Acute Liver Failure In Non-Ambulatory Duchenne Muscular Dystrophy Patients Following Elevidys; Says Two Reported Deaths In Non-Ambulatory DMD Patients Appear To Be Related To Treatment With Elevidys

<a href="https://www.globenewswire.com/Tracker?data=GzwNc3MnbS_tvJZ1O4qMRvEi8V2fRFeS4ThyqxlfRvds7uCkqbbv8ZCvZTt7aUjbw0Cfg-hLntGJFQgJKpGQP0nd_0sQuDZWo1RBBLgWLnHcb884VT5-sIUR4BD_nU44Ibv307THBg1qxYqxir-QTeV0uNQR5jkjaFUGi4x938BBR-lPm_PMfhtU2U86JeLE40yUKdIIwYYp3KLmgrbXoJHwnrTmwZlSRo-ZkLn5bNN_NaHdVjPKX5PDGMUVMWHTimEvzRnCQbY-IuAkgLomgA==">Cue Biopharma, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA). The FDA reviewed the first-in-human trial design, including the Company's plan for dose escalation, proposed populations and safety monitoring plan. On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies. CUE-401 is the Company's lead autoimmune asset, a first-in-class bispecific fusion protein/molecule designed to induce and expand regulatory T cells (Tregs) in vivo through the co-activity of transforming growth factor beta (TGF-β) and a modified variant of interleukin 2 (IL-2).

Cue Biopharma Receives FDA Pre-IND Feedback For Lead Autoimmune Therapy CUE-401; Plans IND Filing Pending Final Studies

SMSI

Smith Micro Software Receives Nasdaq Minimum Bid Price Notice

Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.46) by 8.7 percent. This is a 17.65 percent increase over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $1.389 million which missed the analyst consensus estimate of $1.711 million by 18.80 percent. This is a 10.24 percent increase over sales of $1.260 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

ATEX

Anterix Q4 Adj. EPS $(0.42) Beats $(0.46) Estimate, Sales $1.389M Miss $1.711M Estimate

ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) has outperformed the market over the past 5 years by 5.63% on an annualized basis producing an average annual return of 20.42%. Currently, ONEOK has a market capitalization of $50.32 billion. 
Buying $1000 In OKE: If an investor had bought $1000 of OKE stock 5 years ago, it would be worth $2,614.74 today based on a price of $80.56 for OKE at the time of writing.
<h3>ONEOK's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750797921_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning ONEOK Stock In The Last 5 Years

FedEx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) reported financial results for the fourth quarter of fiscal 2025 after the market close on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/06/b46082572/fedex-reports-fourth-quarter-diluted-eps-of-6-88-and-adjusted-diluted-eps-of-6-07">of the report</a>.
Q4 Earnings: FedEx reported fourth-quarter revenue of $22.2 billion, beating analyst&nbsp;<a href="http://benzinga.com/quote/FDX/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $21.84 billion, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company reported fourth-quarter adjusted earnings of $6.07 per share, beating analyst estimates of $5.87 per share.
Operating results for the company&#8217;s Federal Express segment improved during the quarter, driven by cost reduction benefits. FedEx said its Freight segment operating results decreased in the quarter due to lower fuel surcharges, reduced weight per shipment, higher healthcare costs, increased wage rates and one fewer operating day.
FedEx returned $4.3 billion to shareholders in fiscal 2025 through repurchases and dividends. The company had $2.1 billion remaining under its buyback as of May 31.
&#8220;I am proud of the FedEx team for a solid finish to the fiscal year, delivering excellent service for our customers while achieving our structural cost reduction target, in the face of ongoing headwinds,&#8221; said Raj Subramaniam, president and CEO of FedEx.
&#8220;We will continue to leverage the unique scale and flexibility of our global network to support our customers as the demand environment evolves.&#8221;
Guidance: FedEx expects first-quarter adjusted earnings to be between $3.40 and $4 per share versus estimates of $4.15 per share. The company expects revenue to be flat to up 2% on a year-over-year basis in the first quarter.
FedEx is targeting permanent cost reductions of $1 billion from its DRIVE and Network 2.0 transformation programs in fiscal 2026. 
FedEx executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
FDX Price Action: <a href="http://benzinga.com/quote/fdx" target="_blank" rel="noreferrer noopener">FedEx shares</a> were down 4.40% in after-hours, trading at $219.41 at the time of publication on Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/46018581/trumps-tariffs-trigger-layoffs-monopoly-maker-hasbro-slashes-jobs-these-companies-are-cutting-too">Trump&#8217;s Tariffs Trigger Layoffs: Monopoly Maker Hasbro Slashes Jobs — These Companies Are Cutting Too</a></li>
<li><a href="https://www.benzinga.com/news/financing/25/06/46066370/fred-smith-was-told-by-yale-professor-that-his-overnight-delivery-idea-would-only-earn-him-a-c-the-fedex-founder-turned-it-into-a-54-billion-logistics-giant">Fred Smith Was Told By Yale Professor That His Overnight-Delivery Idea Would Only Earn Him A &#8216;C&#8217; — The FedEx Founder Turned It Into A $54 Billion Logistics Giant</a></li>
</ul>
Photo: K.G. Yon/Shutterstock.

Guidance

After-Hours Center

Movers

FedEx Q4 Earnings: Revenue, EPS Beat Estimates, Shares Slide On Soft Guidance

OUTFRONT Media Announces Restructuring And Reduction In Force Plan; Plan To Reduce Workforce By About 120 Employees; Estimates $18.6M In Restructuring Charges

WIIM

FedEx shares are trading lower following soft Q1 guidance.

With President Donald Trump brokering a <a href="https://www.benzinga.com/news/politics/25/06/46072859/trump-says-israel-is-not-going-to-attack-iran-after-ceasefire-violation-turn-around-and-head-home">ceasefire between Israel and Iran</a>, the major indices have predictably swung higher. Still, this normalization shifts the fundamental spotlight back to the economy, where an underlying truth cannot be avoided: <a href="https://www.benzinga.com/news/25/04/44916124/frozen-pizza-sales-surge-like-2009-recession-as-americans-cut-back-on-dining-out-amid-economic-strain">many consumers are struggling</a> amid significant challenges. From a pragmatic perspective, this dynamic could benefit TJX Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>). As an off-price department store, TJX specializes in the very discounts that consumers are looking for right now.
First, <a href="https://www.youtube.com/watch?v=dey0Q0MGmG8">statements</a> made by Federal Reserve Chair Jerome Powell to House lawmakers earlier today indicated that the central bank is in a wait-and-see mode. That's despite <a href="https://www.benzinga.com/news/politics/25/06/45898797/trump-and-jd-vance-push-fed-to-slash-interest-rates-after-mild-inflation-report-calling-current-policy-monetary-malpractice">increasing pressure from Trump</a> to implement rate cuts. However, Powell asserted that the Fed must fully understand the broader implications of the Trump administration's tariffs before initiating a change to monetary policy.
Reading between the lines, the central bankers are acknowledging the concerns of the consumer as it relates to costs of living. On a fundamental note, this circumstance may aid TJX stock due to the underlying discount retail business model.
Second, the specific catalyst that may help boost TJX is the <a href="https://www.benzinga.com/markets/options/25/06/45984657/kr-stock-trade-down-effect-earnings-reversal">trade-down effect</a>. This phenomenon refers to consumers, when faced with tough economic conditions, choosing to buy either less of a product or lower-cost alternatives. As I stated prior to the first-quarter earnings report of grocery giant Kroger Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), this dynamic could help lift KR stock out of its then-slump.
It's worth pointing out that the actual print overall came in <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46059125/these-analysts-raise-their-forecasts-on-kroger-after-stronger-than-expected-q1-earnings">better than expected</a>, sending Kroger shares dramatically higher. With TJX <a href="https://www.benzinga.com/quote/TJX/earnings">reporting earnings in August</a>, investors will have to wait for a substantive driver. However, traders may be able to extract quick profits in the interim.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1000" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24151238/TJX-stock-technical-analysis.jpg" alt="" class="wp-image-960493" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24151238/TJX-stock-technical-analysis.jpg 1000w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24151238/TJX-stock-technical-analysis-300x179.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24151238/TJX-stock-technical-analysis-768x458.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px" /><figcaption class="wp-element-caption">Image by TradingView</figcaption></figure>
From a technical viewpoint, there appears to be a resistance level at around $128. The idea here is that TJX stock could potentially hit this level within a few weeks, thus triggering an option strategy's profitability zone.
<h2 class="wp-block-heading">Using Statistical Analysis To Pinpoint A Strategy For TJX Stock</h2>
While both the fundamental and technical frameworks for TJX stock are arguably bullish, these methodologies only speak to the potential magnitude component of the underlying thesis or the price chart's y-axis. But with options trading, the x-axis is also critical; otherwise, the right thesis at the wrong time may still result in a complete loss of principal in a debit-based strategy.
To better understand the lay of the land, traders must view the problem probabilistically, which requires statistical analysis. At first glance, this process sounds easy: just take the frequency of the desired outcome divided by the total number of events in the dataset. However, this approach only calculates what's known as the derivative probability or the odds of an outcome across the dataset's entire distribution.
Unfortunately, derivative probabilities aren't very useful. For instance, air travel is statistically considered a safe form of travel but this insight is aggregated across the experiences of all flyers. If your pilot is inebriated or air traffic control employees are under extreme stress, the odds of something bad happening dramatically increase.
In other words, the probabilities that we're looking for is conditional. This refers to the odds of an outcome based off a specific subset of the data. But in order to extract conditional probabilities, the dataset (price action in this case) must be organized in discrete states to distinguish one state from another. Therefore, my metric of choice is market breadth — sequences of accumulative and distributive sessions.
Discrete states represent the <a href="https://brilliant.org/wiki/markov-chains/">backbone</a> of Markov chain analysis, which is the mathematical principle that I have been utilizing in the past few months. As it relates to TJX stock, the past two months' price action can be converted into discrete states under the sequencing format "4-6-U": four up weeks, six down weeks, with a net positive trajectory across the 10-week period.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24150858/TJX-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-960487" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24150858/TJX-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24150858/TJX-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24150858/TJX-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24150858/TJX-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Admittedly, this process compresses the magnitude dynamism of TJX stock into a simple binary code. However, the benefit from a statistical standpoint is that the last-10-week intervals can be identified as unique behavioral states. Using past analogs, we can determine that when the 4-6-U sequence flashes, there's a 63.64% chance that the following week's price action results in upside, with a median return of 2.28%.
Projecting an upside target isn't an exact science due to the market's usual chaos. However, if the bulls maintain control of the market, a rational target is $128.20 over the next three to four weeks — roughly aligning with the aforementioned resistance level.
<h2 class="wp-block-heading">A Bold Debit Call Spread For The Risk-Tolerant Speculator</h2>
For traders interested in rolling the mathematical dice, the 127/128 bull call spread expiring July 18 may be tempting. This transaction involves buying the $127 call and simultaneously selling the $128 call, for a net debit paid of $46 (the most that can be lost in the trade). Should TJX stock rise through the short strike price ($128) at expiration, the maximum reward is $54, a payout of over 117%.
What makes this trade so enticing is the implied shift in sentiment regime of the 4-6-U sequence. As a baseline, the chance that TJX stock may rise over any given week is 54.11%. Therefore, the aforementioned sequence boosts the bullish odds quite significantly. In other words, the call spread may be favorably mispriced.
Part of the reason for the mispricing is that the vast majority of Wall Street analysts rely on interpretations of non-stationary price signals or financial ratios. Generally, these interpretations are vague, presenting difficulties for traders. With the above discrete-state analysis, we're using math and science to help pinpoint our strategic framework.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/06/46061830/crwd-stock-gains-relevance-iran-cyberattack-threat">Options Corner: CrowdStrike Gains Relevance As Iran Poses Cyber Retaliation Threat</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

Politics

Events

Options Corner: TJX Companies May Be Poised For Upside As Shoppers Hunt For Discounts

QuantumScape shares are trading higher after the company achieved a key 2025 milestone by successfully integrating its advanced Cobra separator process into baseline cell production.

Mirion Technologies shares are trading higher after the company announced a partnership with Westinghouse to provide digital Ex-core Nuclear Instrumentation Systems.

Macro Economic Events

Econ #s

Economics

UPDATE: USA API Weekly Crude Oil Stock 4.277M Barrel Draw Vs 600K Barrel Draw Est

<a href="https://www.bloomberg.com/news/articles/2025-06-24/best-buy-divests-home-care-unit-bought-for-400-million-in-2021?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-24/best-buy-divests-home-care-unit-bought-for-400-million-in-2021?embedded-checkout=true</a>

'Best Buy Divests Home Care Unit Bought for $400 Million in 2021'- Bloomberg

Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) reported quarterly sales of $1.39 million which missed the analyst consensus estimate of $1.71 million by 18.80 percent. This is a 10.24 percent increase over sales of $1.26 million the same period last year.

Anterix Q4 Sales $1.39M Miss $1.71M Estimate

Achieves Key 2025 Goal, Bringing its Technology Closer to Commercialization
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quantumscape.com%2F&amp;esheet=54281769&amp;newsitemid=20250624801952&amp;lan=en-US&amp;anchor=QuantumScape+Corporation&amp;index=1&amp;md5=f56eb983a9f8bd5b586e236b4698c776">QuantumScape Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>), a global leader in next-generation solid-state lithium-metal battery technology, today announced a major milestone in the scale-up of its production capabilities: the successful integration of its advanced <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fyoutu.be%2FoJgoe_CHTKM&amp;esheet=54281769&amp;newsitemid=20250624801952&amp;lan=en-US&amp;anchor=Cobra+separator+process&amp;index=2&amp;md5=81007103950141134d8b7020fa8678e8">Cobra separator process</a> into baseline cell production.
Cobra forms the foundation of QS's high-throughput, continuous-flow separator production platform. Designed to enable faster, more energy-efficient production with a smaller equipment footprint compared to earlier processes, Cobra represents a step-change improvement in ceramic separator manufacturing. Compared to the prior-generation Raptor process, Cobra offers a ~25x improvement in heat treatment speed and occupies a fraction of the physical space per film start – key advantages in the design of a scalable gigafactory production line.

QuantumScape Achieves Key 2025 Milestone In The Scale-Up Of Its Production Capabilities With The Successful Integration Of Its Advanced Cobra Separator Process Into Baseline Cell Production

RKLB

Rocket Lab Announces 'Get The Hawk Outta Here' Mission Launch Window Opens Jun. 26 At 17:00 UTC

Management

JACK

Jack In The Box's Shannon McKinney Returns As Senior Vice President And COO

Superior Industries International Receives NYSE Notice For Non-Compliance With Listing Rules

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 14.5% on an annualized basis producing an average annual return of 29.29%. Currently, Canadian Natural Res has a market capitalization of $65.98 billion. 
Buying $1000 In CNQ: If an investor had bought $1000 of CNQ stock 5 years ago, it would be worth $3,686.55 today based on a price of $31.52 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750797029_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CANN">Trees</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CANN#OTC">CANN</a>) shares closed up 124.58% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 100.00% at $0.0002</li>
<li><a href="https://www.benzinga.com/quote/PHOT">GrowLife</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHOT#OTC">PHOT</a>) shares closed up 100.00% at $0.0004</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 47.20% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 28.95% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 14.37% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 13.28% at $0.56</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 13.16% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 8.51% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 7.89% at $7.25</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 7.55% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 6.52% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed up 6.15% at $0.88</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 6.10% at $0.38</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 4.28% at $3.41</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 3.13% at $1.36</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 3.09% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 21.84% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 14.39% at $9.72</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 13.04% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 12.62% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 9.09% at $0.001</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 6.81% at $0.52</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 4.37% at $0.05</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BBRRF

BLGVF

CANN

CBDY

CLSH

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

FFNTF

ITHUF

KAYS

LMLLF

MGWFF

OILFF

PHOT

TCNNF

TGIFF

TLRY

XXII

YCBD

ZDPY

Bullish Sentiment Across The Cannabis Space - Check Full Movers For June 24, 2025

Comments

Pacer Trendpilot 100 ETF

Interés en corto

Pacer Trendpilot 100 ETF (NASDAQ:PTNQ), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL